Header Logo

Connection

Annette Langer-Gould to Fingolimod Hydrochloride

Back to Details
This is a "connection" page, showing publications Annette Langer-Gould has written about Fingolimod Hydrochloride.
Annette Langer-Gould
Connection Strength
0.948
Fingolimod Hydrochloride
  1. Multiple Sclerosis, Disease-Modifying Therapies, and Infections. Neurol Neuroimmunol Neuroinflamm. 2023 Nov; 10(6).
    View in: PubMed
    Score: 0.235
  2. Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy. Neurol Neuroimmunol Neuroinflamm. 2023 07; 10(4).
    View in: PubMed
    Score: 0.228
  3. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Ann Neurol. 2020 05; 87(5):688-699.
    View in: PubMed
    Score: 0.183
  4. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol. 2020 02 01; 77(2):184-191.
    View in: PubMed
    Score: 0.182
  5. The pill times 2: what every woman with multiple sclerosis should know. Neurology. 2014 Feb 25; 82(8):654-5.
    View in: PubMed
    Score: 0.120

© 2024 Kaiser Permanente